About the Company
We do not have any company description for PharmaCyte Biotech, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 ...
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing.
PharmaCyte Biotech Secures $7 Million Private Placement
PharmaCyte Biotech ( ($PMCB) ) has issued an update. On August 17, 2025, PharmaCyte Biotech, Inc. announced a $7 million private placement ...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s ...
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ( ...
Why Are PharmaCyte Shares Moving Higher On Thursday?
PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of its CypCaps trial product candidate. These results were from ...
PharmaCyte Biotech Inc. Research & Ratings | PMCB | Barron's
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary ...
Pharmacyte Biotech Inc (PMCB-Q) Quote - Press Release
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a ...
PharmaCyte Biotech Completes Final cGMP Audit of Manufacturing ... - Nasdaq
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today ...
PMCB - PharmaCyte Biotech Inc Valuation | Morningstar
Review the current valuation for PharmaCyte Biotech Inc (PMCB:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Pharmacyte Biotech Inc. | BioWorld
Pharmacyte Biotech Inc. is now in a series of 30-day cycles with the FDA as a planned phase IIb study of its lead candidate has been placed on hold. On Sept. 2, Pharmacyte submitted its IND for a ...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s ...
PharmaCyte Biotech, Inc. announces it has made a $5 million investment in Femasys, Inc., a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad ...
Similar Companies
Loading the latest forecasts...